Home
AffaMed Therapeutics

AffaMed Therapeutics Market Share Analysis for February 2026

to help more patients access innovative treatments

Industry: N/A

Domainaffamed.com

Year Founded2019

Employees51 - 200

Annual Revenue--

AffaMed Therapeutics

AffaMed Therapeutics (including company regionals)

affamed.com

See more website traffic and engagement information

Total visits to AffaMed Therapeutics's top domains

Understand AffaMed Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

affamed.com272

See more with Sales Intelligence

Avg. visit duration in AffaMed Therapeutics's top domains

Analyze AffaMed Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

affamed.com00:00:18

See more with Sales Intelligence

Avg. pageviews on AffaMed Therapeutics's top domains

See how AffaMed Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

affamed.com1.40

See more with Sales Intelligence

AffaMed Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by AffaMed Therapeutics

These are the website technologies, by industry, used by AffaMed Therapeutics top domains

Conversion & Analytics (2)

CNZZ

Advertising (1)

Baidu Ads

Email Services (1)

Microsoft Exchange Online

Mobile (1)

Meta Viewport

News & Signals from AffaMed Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAllgenesis Biotherapeutics Inc. partnered with AffaMed on Sep 1st '21.In September 2021, Allgenesis announced it entered into a licensing agreement with AffaMed Therapeutics for the development and commercialization of AG-73305 in Greater China, South Korea, and multiple ASEAN markets.

NewsAffaMed launches EVOLUX.AffaMed Technologies announces licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL.

NewsVistaGen Therapeutics Inc. partnered with AffaMed on Jun 1st '20.In June 2020, VistaGen entered into a strategic licensing and collaboration agreement with AffaMed Therapeutics for the clinical development and commercialization of PH94B in China, South Korea, and Southeast Asia.